We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

71 hedge funds and large institutions have $332M invested in Avadel Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more call options, than puts

Call options by funds: $1.45M | Put options by funds: $611K

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

11% more funds holding

Funds holding: 64 → 71 (+7)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less capital invested

Capital invested by funds: $342M → $332M (-$10.3M)

16% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 25

Holders
71
Holders Change
+7
Holders Change %
+10.94%
% of All Funds
2.06%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
13
Increased
21
Reduced
25
Closed
6
Calls
$1.45M
Puts
$611K
Net Calls
+$840K
Net Calls Change
+$3.4M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.64M
2
PC
PointState Capital
New York
+$5.75M
3
KCM
Kennedy Capital Management
Missouri
+$4.42M
4
TI
Turner Investments
Pennsylvania
+$2.71M
5
Morgan Stanley
Morgan Stanley
New York
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$9.45M
2
BC
Broadfin Capital
New York
-$3.77M
3
PA
Perceptive Advisors
New York
-$2.73M
4
Millennium Management
Millennium Management
New York
-$2.21M
5
Jennison Associates
Jennison Associates
New York
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
51
Condor Capital Management
New Jersey
$152K -$28.2K -1,963 -16%
KIA
52
Kopp Investment Advisors
Minnesota
$148K -$10.3K -715 -6%
Arrowstreet Capital
53
Arrowstreet Capital
Massachusetts
$145K +$146K +10,155 New
Wells Fargo
54
Wells Fargo
California
$129K +$129K +9,004 New
Group One Trading
55
Group One Trading
Illinois
$122K +$96.8K +6,736 +375%
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$93K +$7.19K +500 +8%
MTIP
57
Magee Thomson Investment Partners
California
$77K +$78.5K +5,459 New
Northern Trust
58
Northern Trust
Illinois
$30K -$219K -15,233 -88%
GXMC
59
Global X Management Company
New York
$22K -$7.62K -530 -26%
LTFS
60
Ladenburg Thalmann Financial Services
Florida
$20K – – –
Lazard Asset Management
61
Lazard Asset Management
New York
$14K +$14.9K +1,040 New
Bank of America
62
Bank of America
North Carolina
$11K +$8.62K +600 +387%
Invesco
63
Invesco
Georgia
$10K +$1.03K +72 +11%
WA
64
WFG Advisors
Texas
$8K – – –
WC
65
Whitnell & Co
Illinois
$7K – – –
BRWM
66
B. Riley Wealth Management
Tennessee
$5K – – –
Barclays
67
Barclays
United Kingdom
$4K – – –
Ameriprise
68
Ameriprise
Minnesota
$2K +$158 +11 +11%
TRCT
69
Tower Research Capital (TRC)
New York
$1K -$7.72K -537 -84%
GSC
70
Ground Swell Capital
South Carolina
$1K +$661 +46 New
HMS
71
Hanseatic Management Services
New Mexico
$1K +$1.5K +104 New
CCM
72
Consonance Capital Management
New York
– -$9.45M -630,178 Closed
GTC
73
Ghost Tree Capital
New York
– -$1.13M -75,000 Closed
GACM
74
Green Arrow Capital Management
New York
– -$375K -25,000 Closed
IHM
75
Iguana Healthcare Management
New York
– -$375K -25,000 Closed
1 2
3
4

AVDL Hedge Fund Activity: Q3 2014 in Review

71 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2014, worth a combined $332M — down 3% from $342M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AVDL positions and 6 closed out — a net gain of 7 holders — while 21 added to existing stakes and 25 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $6.64M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $9.45M sold.

  • 71 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2014, up from 64 in Q2 2014.
  • Funds reported $332M of Avadel Pharmaceuticals stock for Q3 2014, down 3% quarter-over-quarter.
  • 13 funds opened new Avadel Pharmaceuticals positions in Q3 2014 and 6 closed out, a net change of +7 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2014 was T. Rowe Price Associates, an estimated $6.64M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2014 was Consonance Capital Management, an estimated $9.45M sold.

Based on aggregated 13F filings for Q3 2014.